GSK plc GSK reported fourth-quarter 2024 core earnings of 59 cents per American depositary share (ADS), which beat the Zacks ...

GSK was able to offset the decline thanks to a better-than-expected performance for its cancer medicines and HIV therapeutics ...

Q4 2024 Management View CEO Dame Emma Walmsley highlighted that GSK achieved 8% sales growth in 2024, reaching over £31 billion, with specialty medicines driving performance. Core operating profit ...

GSK's Jemperli wins EU approval for broader use in advanced endometrial cancer, showing improved survival and significant trial results.

The FDA has cleared GSK's PD-1 inhibitor Jemperli as a treatment for all adult patients with primary advanced or recurrent endometrial cancer, a key part of the company's growth ambitions for the ...

GSK and the University of Oxford have entered a new research partnership to launch an immuno-prevention programme.

The European Commission approves GSK's Jemperli plus chemotherapy to treat all adult patients with primary, advanced or recurrent endometrial cancer.

European Commission approves GSK’s Jemperli plus chemotherapy to treat patients with primary advanced or recurrent endometrial cancer: London, UK Tuesday, January 21, 2025, 09:0 ...

Jemperli is a programmed death receptor-1 (PD-1)-blocking antibody and forms the backbone of GSK's immuno-oncology research and development program. The drug is currently being studied in various ...

IDRX-42 adds to GSK’s existing gastrointestinal cancer programmes, which include ongoing clinical trials with checkpoint inhibitor Jemperli (dostarlimab) and the B7-H3-targeted antibody-drug ...